Scopolamine Market Demands and Growth Prediction 2018 to 2026

Press Release

Scopolamine is an oral, intravenous, ophthalmic or topical drug derived from plants of the nightshade family (Solanaceae), specifically Hyoscyamus Niger and Atropa belladonna, with anticholinergic, antiemetic and antivertigo properties. It has applications in prevention of nausea, vomiting, and dizziness associated with motion sickness and recovery from anesthesia and surgery. Scopolamine may also be used to treat certain stomach or intestinal problems, such as spastic muscle states, diverticulitis, irritable bowel syndrome, Parkinson-like conditions etc.

Request For a Sample Copy of This Business Report : https://www.coherentmarketinsights.com/insight/request-sample/1965

Market Dynamics

Changing lifestyle that involves minimal or absolutely no physical work in a routine life are responsible for the malfunctioning of the digestive as well as gastrointestinal system. Increasing number of population adopting long-hour sedentary work lifestyle are likely to be affected with gastrointestinal disorders such as irritable bowel syndrome and thus are responsible to support growth of the global scopolamine market.

However, various side-effects observed while using these drugs such as retarded motion, drowsiness, and diluted pupils, may limit their growth to some extent in the near future.

Increasing prevalence of motion sickness is expected to drive growth of the scopolamine market

Psychological stress is considered as one of the most important factors in the development of motion sickness. The psychological stress impacts intestinal motility, intestinal sensitivity, permeability, and secretion that is co-related with the mucosal immune activation and alterations in the central nervous system. According to a survey by Buscopan IBS Relief in 2016, stress was the cause for seven out of ten patients suffering from gastrointestinal pain. Thus, increasing number of population suffering from stress and anxiety disorder are expected to fuel growth of the global scopolamine market.

Use of scopolamine in Alzheimer’s disease may prove useful as a diagnostic or staging test in the evaluation of the cholinergic system in dementia, which provides opportunities to the researchers to explore application of these drugs for other neurological disorders, which in turn is driving the market growth over the forecast period.

However, abuse of these drugs in various regions illegally, may restrict growth of the scopolamine market during the forecast period. For instance, this drug is more common and easily available in Colombia, where it is used to make victims carry out sexual assaults and robberies. Furthermore, online availability of this drugs at low cost, which are abuse by sexual predators and robbers frequently in the various European regions (in UK, scopolamine can be bought online for only US$ 12.8) might bring stringent regulations against the manufacturing and marketing of this drug in the near future which may affected growth of the scopolamine market.

Key players operating in the global scopolamine market include Baxter International Inc., GlaxoSmithKline plc. Novartis AG, Perrigo Company plc., Caleb Pharmaceuticals, Inc., Myungmoon Pharma Co. LTD., Alchem International, Phytex Australia, Centroflora-Cms, Alkaloids of Australia, and Fine Chemicals Corporation.

Purchase This Premium Report : https://www.coherentmarketinsights.com/insight/buy-now/1965

Detailed Segmentation:

  • Global Scopolamine Market, By Dosage Form:
    • Tablet
    • Syrup
    • Injection
    • Patch
    • Others
  • Global Scopolamine Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Scopolamine Market- Regional Analysis

Scopolamine Market is segmented into six major regions- North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Increasing consumption of unhealthy food leading to obesity and other stomach related infections act as one of the major factors driving growth of the scopolamine market in North America region. According to an article published in the Brandon Gaille, in 2017, junk food accounts for 28.8% of the total caloric intake of an average American. Consumption of unhealthy food in large quantity increases the risk of developing irritable bowel syndrome, which is acting as a driving factor for the global scopolamine market growth.

The Asia Pacific region is estimated to witness significant growth in the scopolamine market, owing to presence of small and medium size companies, increased expenditure on healthcare, and growing medical tourism for surgeries as transdermal scopolamine has been used frequently during surgeries to recover from anesthesia induced vomiting and nausea.